A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection
Selvakumar Subbian
Frontiers in Immunology, 2023
View PDFchevron_right
Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury
Christian Bime
Translational Research, 2021
View PDFchevron_right
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury
Esteban Morcillo
British Journal of Pharmacology, 2009
View PDFchevron_right
Roxadustat for SARS-CoV-2 Infection: Old Signaling Raised New Hopes
Saeed M Kabrah
Drugs in R&D
View PDFchevron_right
PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking
hayder M Al-kuraishy
Review, 2021
View PDFchevron_right
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
Mara Massimi
International Journal of Molecular Sciences
View PDFchevron_right
New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19
Dr Maram Eltabaa
European Journal of Pharmacology, 2020
View PDFchevron_right
Tumor Necrosis Factor Alpha Converting Enzyme (TACE) as Possible Therapeutic Target in SARS-CoV-2 Induced Acute Respiratory Distress Syndrome (ARDS)
João Batista Júnior
ChemRxiv, 2020
View PDFchevron_right
The effect of drugs used in rheumatology for treating SARS-CoV2 infection
Manuela Maria Giallanza
Expert Opinion on Biological Therapy, 2020
View PDFchevron_right
Understanding the Systemic Effects of COVID-19: Possible Clues to Potential Therapeutic Approaches
Lawal Babatunde saheed
International journal of tropical diseases, 2022
View PDFchevron_right
Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation
Marco Cardone
Frontiers in Immunology, 2020
View PDFchevron_right
COVID-19 and phosphodiesterase enzyme type 5 inhibitors
Ali Al-Gareeb
Journal of Microscopy and Ultrastructure, 2020
View PDFchevron_right
A Concise Review of the Popularised Drugs Used For The Management of COVID-19 (SARS-CoV-2
Fortune Journals
View PDFchevron_right
Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease
Gurudeeban Selvaraj
Journal of Personalized Medicine
View PDFchevron_right
Potential COVID-19 Immunomodulators and Beyond: NSAIDs Might Inhibit SARS CoV-2 ORF Proteins Induced Caspase Activation, Necroptosis and Endoplasmic Reticulum Stress
Mina kelleni
View PDFchevron_right
Covid-19 infection and mortality - A physiologist's perspective enlightening clinical features and plausible interventional strategies
Zaher Armaly
American Journal of Physiology-Lung Cellular and Molecular Physiology, 2020
View PDFchevron_right
COVID-19: inflammatory responses, structure-based drug design and potential therapeutics
Dr. Manoj Kumar Goshisht
Molecular Diversity, 2021
View PDFchevron_right
Pyronaridine Protects Against SARS-CoV-2 in Mouse
Sabrina Setembre Batah
2021
View PDFchevron_right
Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future
Mauro Martins
Trends in Pharmacological Sciences, 1997
View PDFchevron_right
The preclinical pharmacology of roflumilast – A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
E. Morcillo, Giuseppe Lungarella
Pulmonary Pharmacology & Therapeutics, 2010
View PDFchevron_right
The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach
Lisa Olive
Life Sciences, 2020
View PDFchevron_right
The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells
Madhav Sharma
Virulence, 2021
View PDFchevron_right
Potential therapeutic and pharmacological strategies for SARS-CoV2
salma soudi
Journal of Pharmaceutical Investigation
View PDFchevron_right
Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome?
Nicola Curtin
British Journal of Pharmacology
View PDFchevron_right
Anti-rheumatic drugs as potential anti-inflammatory, immunomodulatory agents against COVID-19: A systematic review
Reza Shiari
Pharmaceutical Sciences
View PDFchevron_right
Roflumilast: Review of Phosphodiesterase-4 Inhibitor as Asthma Therapy
Fauna Herawati
Journal of Health Sciences, 2021
View PDFchevron_right
Candidate drugs against SARS-CoV-2 and COVID-19
Dwight McKee
Pharmacological Research, 2020
View PDFchevron_right
COVID-19: Comprehensive Synopsis of Suggested Pathophysiological Mechanisms and Repurposed Drugs
Mathijs Binkhorst
2020
View PDFchevron_right
Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients
R. Priori
Frontiers in Immunology, 2020
View PDFchevron_right
Inflammation in COVID-19 and the Effects of Non-Pharmacological Interventions during the Pandemic: A Review
Álvaro Sanchez
International Journal of Molecular Sciences
View PDFchevron_right